Date Filed | Type | Description |
06/09/2023 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Granted 30,000 restricted stock units
@ $0 |
|
02/02/2023 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 248 shares
@ $10.12, valued at
$2.5k
Sold 991 shares
@ $10.12, valued at
$10k
Sold 661 shares
@ $10.12, valued at
$6.7k
Exercised 500 restricted stock units
@ $0 Exercised 2,000 restricted stock units
@ $0 Exercised 1,333 restricted stock units
@ $0 Granted 10,000 restricted stock units
@ $0 Granted 30,000 options to buy
@ $10.39, valued at
$311.7k
|
|
01/23/2023 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Exercised 122,677 options to buy
@ $5, valued at
$613.4k
|
|
08/25/2022 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 259 shares
@ $7.81, valued at
$2k
Exercised 500 restricted stock units
@ $0 |
|
05/03/2022 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 254 shares
@ $6.62, valued at
$1.7k
Exercised 500 restricted stock units
@ $0 |
|
02/02/2022 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 275 shares
@ $7.58, valued at
$2.1k
Sold 1,099 shares
@ $7.58, valued at
$8.3k
Exercised 500 restricted stock units
@ $0 Granted 12,064 options to buy
@ $7.72, valued at
$93.1k
Granted 4,000 restricted stock units
@ $0 Exercised 2,000 restricted stock units
@ $0 |
|
01/28/2022 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 111 shares
@ $8.09, valued at
$898 Exercised 209 restricted stock units
@ $0 |
|
11/19/2021 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Bought 160 shares
@ $13.1, valued at
$2.1k
|
|
11/02/2021 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 258 shares
@ $17.16, valued at
$4.4k
Exercised 500 restricted stock units
@ $0 |
|
10/28/2021 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 107 shares
@ $16.32, valued at
$1.7k
Exercised 208 restricted stock units
@ $0 |
|
08/03/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/28/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
05/04/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/27/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
02/02/2021 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 1,076 shares
@ $22.07, valued at
$23.7k
Exercised 2,000 restricted stock units
@ $0 Granted 21,000 options to buy
@ $22.07, valued at
$463.5k
Granted 6,000 restricted stock units
@ $0 |
|
01/26/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
12/07/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 662 shares
@ $19.85, valued at
$13.1k
Exercised 1,042 restricted stock units
@ $0 |
|
10/28/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 101 shares
@ $20.9461, valued at
$2.1k
Exercised 208 restricted stock units
@ $0 |
|
09/08/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 348 shares
@ $20.2, valued at
$7k
Exercised 1,041 restricted stock units
@ $0 |
|
07/28/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 70 shares
@ $23.51, valued at
$1.6k
Exercised 209 restricted stock units
@ $0 |
|
06/05/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 349 shares
@ $27.5128, valued at
$9.6k
Exercised 1,042 restricted stock units
@ $0 |
|
04/28/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 70 shares
@ $24.35, valued at
$1.7k
Exercised 208 restricted stock units
@ $0 |
|
03/04/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Paid exercise price by delivering 345 shares
@ $29.5, valued at
$10.2k
Exercised 1,042 restricted stock units
@ $0 |
|
02/13/2020 |
3/A
| Schoenberg Mark (Chief Medical Officer) has filed a Form 3/A on UroGen Pharma Ltd. |
02/04/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Granted 15,000 options to buy
@ $29.41, valued at
$441.2k
Granted 6,000 restricted stock units
@ $0 |
|
01/28/2020 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 322 shares
@ $29.15, valued at
$9.4k
Exercised 833 options to buy
@ $0 |
|
12/05/2019 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Paid exercise price by delivering 343 shares
@ $31.69, valued at
$10.9k
Exercised 1,042 options to buy
@ $0 |
|
11/21/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
09/06/2019 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 343 shares
@ $33.92, valued at
$11.6k
Exercised 1,041 options to buy
@ $0 |
|
06/06/2019 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Paid exercise price by delivering 343 shares
@ $35.05, valued at
$12k
Exercised 1,042 options to buy
@ $0 |
|
03/22/2019 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Bought 272 shares
@ $37.009, valued at
$10.1k
|
|
03/07/2019 |
4
| Schoenberg Mark (Chief Medical Officer) has filed a Form 4 on UroGen Pharma Ltd.
Txns:
| Sold 1,991 shares
@ $37.3, valued at
$74.3k
Exercised 1,042 options to buy
@ $0 |
|
03/07/2019 |
3/A
| Schoenberg Mark (Chief Medical Officer) has filed a Form 3/A on UroGen Pharma Ltd. |
01/29/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |